Four biotechs haul in $303M+ from a fresh burst of IPOs
Despite the longest-ever US government shutdown subduing IPO activity in the first-quarter — healthcare IPOs dominated, accounting for 70% of the 20 IPOs in the region, according to accounting firm Ernst & Young. Interest in the sector has far from cooled — with four drug developers focusing on a range of conditions from the ever-popular immuno-oncology to failure-friendly Alzheimer’s — set to make their public debuts on Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.